Methadone reduces risk of HIV transmission in people who inject drugs, say experts

October 5, 2012
Methadone reduces risk of HIV transmission in people who inject drugs, say experts

(Medical Xpress)—People who inject drugs (PWID) can significantly reduce their risk of HIV infection with the use of opiate substitution treatments such as methadone, as suggested by an international team of researchers in a paper published today on bmj.com.

Injection drug use (IDU) is a major risk factor for the and AIDS and / AIDS accounts for nearly one fifth of the burden of disease among people who inject drugs. It is estimated that around five to ten per cent of HIV infections worldwide are due to IDU. and buprenorphine are the main forms of drug prescribed for addicts and are frequently prescribed as opiate substitution therapies (OST). There is good evidence to suggest that OST reduces drug-related , and some of the associated with injecting risk, but to date there has been no quantitative estimate of the effect of OST in relation to HIV transmission.

Authors from around the world (US, Canada, Europe and Australia) therefore carried out a review and pooled analysis of several published and unpublished studies from multiple countries (including USA, Canada, UK, the Netherlands, Austria, Italy, Thailand, Puerto Rico and China) to determine the association between OST and HIV transmission amongst people who inject drugs. The nine studies looked predominantly at males between 26 and 39-years-old and totalled 819 incidences of with 23,608 person-years of follow-up.

After analysing these studies, authors found that OST was associated with a 54 per cent reduction in risk of HIV infection among PWID. There were differences between the studies, including different background rates of HIV infection: this made it impossible to calculate an "absolute risk reduction" for HIV infection that would translate to all settings. And not all studies reported adjustments to the intervention to take account of other factors that might influence the association between OST and HIV infection. But the impact of OST on HIV was strong and consistent in further analyses in the paper. There was weak evidence to suggest that longer duration of OST exposure may be associated with greater benefit.

Matthew Hickman, the study's Principal Investigator and Professor in Public Health and Epidemiology at the University of Bristol said: "Increases in HIV incidence have been reported among people who inject drugs in a number of different countries in recent years and there is now strong evidence demonstrating the association between OST and the reduced risk of ."

There are several countries where OST remains illegal or severely restricted. The authors say that this study calls for a global scale up of harm reduction interventions in order to reduce the transmission of HIV among people who inject drugs – especially in countries with high rates of HIV.

An accompanying editorial praises MacArthur and colleagues for showing the extent to which OST reduces the transmission of HIV. Linda Gowing from the Discipline of Pharmacology at the University of Adelaide argues however that questions do still remain as further evidence is needed regarding other forms of OST such as . She argues also that as the benefits of OST may be lost when treatment stops, especially if this is not voluntary or relapse to injecting occurs, then policy makers should focus on maximising retention and uptake of people onto OST.

Explore further: IAS urges Russian government to radically reassess counterproductive drug policies

More information: www.bmj.com/cgi/doi/10.1136/bmj.e5945

Related Stories

IAS urges Russian government to radically reassess counterproductive drug policies

June 27, 2011
28 June 2011. Geneva, Switzerland. As Boris Gryzlov, speaker of the Russian state Duma, calls for a "total war on drugs" to tackle Russia's growing drug problem, the International AIDS Society (IAS) urges the Russian government ...

Recommended for you

Scientists find where HIV 'hides' to evade detection by the immune system

October 19, 2017
In a decades-long game of hide and seek, scientists from Sydney's Westmead Institute for Medical Research have confirmed for the very first time the specific immune memory T-cells where infectious HIV 'hides' in the human ...

National roll-out of PrEP HIV prevention drug would be cost-effective

October 18, 2017
Providing pre-exposure prophylaxis (PrEP) medication to men who have sex with men who are at high risk of HIV infection (equivalent to less than 5% of men who have sex with men at any point in time) in England would be cost-effective, ...

Regulatory T cells harbor HIV/SIV virus during antiviral drug treatment

October 17, 2017
Scientists at Yerkes National Primate Research Center, Emory University have identified an additional part of the HIV reservoir, immune cells that survive and harbor the virus despite long-term treatment with antiviral drugs.

New research opens the door to 'functional cure' for HIV

October 17, 2017
In findings that open the door to a completely different approach to curing HIV infections, scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time shown that a novel compound effectively ...

Researchers create molecule that could 'kick and kill' HIV

October 5, 2017
Current anti-AIDS drugs are highly effective at making HIV undetectable and allowing people with the virus to live longer, healthier lives. The treatments, a class of medications called antiretroviral therapy, also greatly ...

A sixth of new HIV patients in Europe 50 or older: study

September 27, 2017
People aged 50 and older comprise a growing percentage of HIV patients in Europe, accounting for one in six new cases in 2015, researchers said Wednesday.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.